Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Obesity

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795375

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795375

Systemic Mastocytosis Treatment

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Systemic Mastocytosis Treatment Market to Reach US$709.1 Million by 2030

The global market for Systemic Mastocytosis Treatment estimated at US$530.9 Million in the year 2024, is expected to reach US$709.1 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. AK-002 Treatment, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$305.2 Million by the end of the analysis period. Growth in the BLU-285 Treatment segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$139.6 Million While China is Forecast to Grow at 4.9% CAGR

The Systemic Mastocytosis Treatment market in the U.S. is estimated at US$139.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$114.8 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Systemic Mastocytosis Treatment Market - Key Trends & Drivers Summarized

Why Is Systemic Mastocytosis Gaining Attention in Precision Medicine?

Systemic mastocytosis (SM) is a rare, hematologic neoplasm characterized by abnormal accumulation of mast cells in various organs such as the skin, bone marrow, liver, and spleen. The disease ranges from indolent forms to aggressive subtypes, with symptoms caused by both organ infiltration and mast cell mediator release (e.g., histamine, tryptase). The complex clinical presentation, often involving anaphylaxis, gastrointestinal dysfunction, and bone pain, makes early diagnosis and personalized treatment essential. Advances in molecular diagnostics-particularly the identification of KIT D816V mutations-have allowed for more accurate disease classification and prognosis. As a result, SM is now at the forefront of targeted therapy development in rare oncology, with a growing number of tailored treatment options being explored and approved.

How Are Targeted Therapies Changing the Systemic Mastocytosis Treatment Landscape?

The introduction of tyrosine kinase inhibitors (TKIs) targeting the KIT mutation has redefined treatment strategies. Avapritinib, a selective inhibitor approved for advanced SM, has shown significant clinical benefit in terms of symptom relief and disease burden reduction. Midostaurin, another KIT-targeted therapy, remains a key treatment for aggressive and advanced forms. Combination therapies and novel agents-such as anti-IgE antibodies and mast cell stabilizers-are being evaluated for managing mediator-related symptoms and co-existing allergic conditions. Additionally, research into immunomodulatory drugs and newer kinase inhibitors is ongoing to address drug-resistant or smoldering SM variants. Personalized dosing strategies, based on mutation load and disease subtype, are further improving therapeutic outcomes and tolerability.

Where Is Treatment Access and Disease Monitoring Improving for SM Patients?

Specialized hematology and rare disease centers are implementing comprehensive SM care programs that combine genomic testing, multidisciplinary care, and longitudinal patient monitoring. Disease-specific scoring tools are being integrated into EHRs to guide therapy selection and track progression. Patient advocacy networks are collaborating with pharmaceutical companies to facilitate compassionate use and expanded access to investigational therapies. Digital platforms are supporting remote symptom tracking and treatment response, especially in countries with limited access to specialists. Increasing awareness among allergists, dermatologists, and oncologists is helping reduce diagnostic latency, a key barrier to timely intervention. The establishment of global SM registries is also improving clinical insight and informing policy development.

The Growth in the Systemic Mastocytosis Treatment Market Is Driven by Several Factors…

It is driven by the availability of mutation-specific targeted therapies, advances in molecular diagnostics, and the expansion of rare disease treatment infrastructure. The approval and commercialization of KIT-targeting TKIs have opened a new therapeutic era for patients with advanced SM. Growing inclusion of SM in rare cancer reimbursement programs and orphan drug pipelines is improving treatment accessibility. Development of companion diagnostics and biomarker-guided monitoring tools is enhancing treatment precision and patient outcomes. Increased research funding, international clinical collaborations, and heightened physician awareness are collectively sustaining momentum in the systemic mastocytosis treatment landscape.

SCOPE OF STUDY:

The report analyzes the Systemic Mastocytosis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment, Other Treatments); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AB Science SA
  • AbbVie Inc.
  • Allakos Inc.
  • AstraZeneca
  • Bayer AG
  • Blueprint Medicines Corp.
  • Bristol-Myers Squibb Company
  • Cogent Biosciences Inc.
  • Deciphera Pharmaceuticals
  • Eli Lilly & Company
  • Glenmark Pharmaceuticals Ltd.
  • Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Mylan NV (now Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38159

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Systemic Mastocytosis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Improved Diagnostic Rates and Classification Guidelines Drive Growth in Systemic Mastocytosis Treatment
    • Advancements in KIT Mutation Inhibitors Expand Therapeutic Possibilities for Advanced SM Subtypes
    • Rising Awareness Among Hematologists and Oncologists Fuels Earlier Treatment Initiation
    • Growth in Targeted Therapy Approvals Accelerates Market Entry of Novel Small Molecules
    • Expansion of Symptom Management Strategies Supports Broader Patient Coverage
    • Development of Non-Cytotoxic Therapies Improves Long-Term Tolerability and Outcomes
    • Emergence of Biomarker-Based Patient Stratification Strengthens Role of Personalized Medicine
    • Increased Enrollment in Clinical Trials Enhances Global Accessibility to Emerging Treatments
    • Improved Risk Classification Systems Facilitate Proactive Treatment for High-Risk Patients
    • Integration of Digital Tools for Symptom Tracking Supports Real-Time Disease Management
    • Demand for Oral Formulations With Lower Systemic Toxicity Drives Market Shift
    • Increased Awareness of Misdiagnosis and Underreporting Promotes Uptake of Confirmatory Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Systemic Mastocytosis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Systemic Mastocytosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for AK-002 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for AK-002 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for BLU-285 Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for BLU-285 Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Brentuximab Vedotin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Brentuximab Vedotin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Crenolanib Besylate Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Crenolanib Besylate Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Systemic Mastocytosis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Systemic Mastocytosis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Systemic Mastocytosis Treatment by Type - AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Type - Percentage Breakdown of Value Sales for AK-002 Treatment, BLU-285 Treatment, Brentuximab Vedotin Treatment, Crenolanib Besylate Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Systemic Mastocytosis Treatment by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Systemic Mastocytosis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!